Evidence map›Paper›PMID 31232696›Full record

ArticleAging2019

TGF-β1 enhances FOXO3 expression in human synovial fibroblasts by inhibiting miR-92a through AMPK and p38 pathways.

Shu-Jui Kuo, Shan-Chi Liu, Yuan-Li Huang, Chun-Hao Tsai, Yi-Chin Fong, Horng-Chaung Hsu, Chih-Hsin Tang

Open access · greenAbstract read
In one paragraph

Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Shu-Jui KuoSchool of Medicine, China Medical University, Taichung, Taiwan.
Shan-Chi LiuDepartment of Medical Education and Research, China Medical University Beigang Hospital, Yunlin, Taiwan.
Yuan-Li HuangDepartment of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.
Chun-Hao TsaiSchool of Medicine, China Medical University, Taichung, Taiwan.
Yi-Chin FongDepartment of Medical Education and Research, China Medical University Beigang Hospital, Yunlin, Taiwan.
Horng-Chaung HsuSchool of Medicine, China Medical University, Taichung, Taiwan.
Chih-Hsin TangSchool of Medicine, China Medical University, Taichung, Taiwan.
China Medical University · TWNational Yang Ming Chiao Tung University · TWAsia University · TWChina Medical University Beigang Hospital · TWChina Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is an age-related disease marked by synovial inflammation and cartilage destruction arising from synovitis, joint swelling and pain. OA therapy that targets the synovium is a promising strategy for mitigating the symptoms and disease progression. Altered activity of the transforming growth factor-β1 isoform (TGF-β1) during aging underlies OA progression. Notably, aberrant forkhead box class O 3 (FOXO3) activity is implicated in the pathogenesis of various age-related diseases, including OA. This study explored the interaction and cross-talk of TGF-β1 and FOXO3 in human osteoarthritis synovial fibroblasts (OASFs). TGF-β1 stimulated FOXO3 synthesis in OASFs, which was mitigated by blocking adenosine monophosphate-activated protein kinase (AMPK) and p38 activity. TGF-β1 also inhibited the expression of miR-92a, which suppresses FOXO3 transcription. The suppression of miR-92a was effectively reversed with the blockade of the AMPK and p38 pathways. Our study showed that TGF-β1 promotes anti-inflammatory FOXO3 expression by stimulating the phosphorylation of AMPK and p38 and suppressing the downstream expression of miR-92a. These results may help to clarify OA pathogenesis and lead to better targeted treatment.

Indexed as

AMP-Activated Protein Kinase KinasesCells, CulturedFibroblastsForkhead Box Protein O3Gene Expression RegulationHumansMAP Kinase Signaling SystemMicroRNAsOsteoarthritisProtein KinasesSynovial MembraneTransforming Growth Factor beta1AMP-Activated Protein Kinase KinasesForkhead Box Protein O3FOXO3 protein, humanMicroRNAsMIRN92 microRNA, humanProtein KinasesTransforming Growth Factor beta1FOXO3miRNA-92aosteoarthritissynovial fibroblastsTGF-β1

Identifiers

PMID31232696
PMCPMC6628998
OpenAlexW2953709645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.